Profit
Title: Multicenter, randomized, double-blind, double-dummy, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of two doses of remibrutinib over 68 weeks in adult patients with moderate-to-severe hidradenitis suppurativa. EudraCT: 2024-513282-39.
Protocol Code: CLOU064J12301.
Study Code: SFRI-0067/2024. Phase: III.
Start Date: 22/09/2025.
Principal Investigator: Cristina Magnoni.
Sponsor: Novartis Farma S.p.A.
Title: Phase II/III, international, multicenter, randomized, double-blind, parallel-group, vehicle-controlled study with an open-label extension to evaluate the efficacy and safety of 1% diacerein ointment for the treatment of generalized epidermolysis bullosa simplex (EBS). EudraCT: 2023-508818-42-00.
Protocol Code: AC-203-EBS-007.
Study Code: SFRI-0125/2023. Phase: II/III.
Start Date: 25/02/2025.
Principal Investigator: Cristina Magnoni.
Sponsor: TWi Biotechnology Inc. Taiwan 8F.
Title: Three-arm, prospective, randomized, controlled, double-blind clinical investigation to evaluate the performance and safety of a hyaluronic acid and silver spray in the management of infected wounds.
Protocol Code: AQ78-19-01 (HYALOSILVER).
Study Code: CE-1225/2020.
Start Date: 18/10/2021.
End date: 10/11/2025.
Principal Investigator: Cristina Magnoni.
Sponsor: Fidia Farmaceutici S.p.A.
Title: Melanoma risk assessment by Artificial Intelligence: a new application for personalised prognosis and treatment.
Protocol Code: MARAI-001.
Study Code: CE-1216/2020.
Start Date: 12/09/2022.
End Date: 07/10/2025.
Principal Investigator: Cristina Magnoni. Sponsor: MapGènia S.L.
Title: Open-label, pivotal clinical trial to confirm the efficacy and safety of autologous grafts containing stem cells genetically modified for epidermis restoration in patients with junctional epidermolysis bullosa.
Protocol Code: HOLOGENE 5.
Study Code: CE-0231/2020. Phase: II/III.
Start Date: 14/07/2022.
End Date: 11/06/2025.
Principal Investigator: Cristina Magnoni.
Sponsor: Holostem S.r.l.
Non-Profit
Title: Understanding the pathogenesis of epidermolysis bullosa–associated cutaneous squamous cell carcinomas to identify potential early biomarkers and therapeutic targets.
Study Code: 28/2025/TESS.
Start Date: 13/10/2025.
Principal Investigator: Chiara Fiorentini.
Sponsor: University of Modena and Reggio Emilia.
Funding: PR-FESR 2021–2027.
Title: Preclinical study of epithelial stem cells in patients with rare genetic diseases of the epithelial tissues.
Protocol Code: MGREDR/2022.
Study Code: CE-0657/2022.
Start Date: 23/06/2025.
Principal Investigator: Cristina Magnoni.
Sponsor: University of Modena and Reggio Emilia.
Title: Retrospective descriptive study of complications and recurrences in patients with severe hidradenitis suppurativa (Hurley III) treated surgically.
Study Code: CE-0017/2025.
Start Date: 15/05/2025.
Principal Investigator: Cristina Magnoni.
Sponsor: University of Modena and Reggio Emilia.
Title: Delay in the diagnosis of cutaneous squamous cell carcinoma due to service interruption is associated with poorer prognosis and modified surgical approaches.
Study Code: CE-740/2023.
Start Date: 23/09/2024.
End Date: 02/09/2025.
Principal Investigator: Cristina Magnoni.
Sponsor: University Hospital of Modena.